Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials
Conclusions
This retrospective analysis of 13 trials showed that continuous erythropoiesis receptor activator once-monthly maintained stable hemoglobin levels across a number of clinically relevant patient subgroups, including those with higher inherent cardiovascular risk. The safety profile was consistent with that previously established in the chronic kidney disease population.
ClinicalTrials.gov identifiers
NCT00413894/NCT00545571/NCT00517413/NCT00560404/NCT00882713/NCT00550680/NCT00576303/NCT00660023/NCT00717821/NCT00642850/NCT00605293/NCT00661505/NCT00699348.
Funding
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Dialysis | Drugs & Pharmacology | Endocrinology | Heart | Hemodialysis | Study | Urology & Nephrology